vii LIST OF TABLES
.Scenarios in which respondents would offer NIPT to AMA and non-AMA patients………………………………………………………….12 Table 3 . Outcomes following a positive NIPT result……………………………………13 Table 4 . Points to include in a discussion with patients about NIPT…………………....16 Table 5 . Respondents' thoughts on the future of NIPT pertaining to sex determination and whole exome sequencing……...……………………….. 
INTRODUCTION
The discovery that cell free fetal DNA exists in maternal blood and is quantifiable (Lo et al., 1997) set the stage for the development of a new prenatal screening method.
By means of massively parallel shotgun sequencing (Chiu et al., 2010; Ehrich et al., 2011; Palomaki et al., 2012) , selective sequencing of chromosomes (Bianchi et al., 2012) and detection via single nucleotide polymorphisms (Zimmermann et al., 2012) , noninvasive prenatal testing (NIPT) can detect select fetal aneuploidies.
Prior to the clinical availability of NIPT, healthcare providers expressed concern over the potential replacement of maternal serum screening by NIPT (de Jong, 2011) , as well as the potential increase in the number of women wishing to pursue NIPT and requiring education by healthcare professionals (Schmitz, Netzer, & Henn, 2009) . A more recent study (Sayres, 2011) of healthcare providers regarding the future integration of NIPT also found that most obstetrics providers thought their patients would desire as much diagnostic information as could be available to them and that if a patient asked for a test it should be provided. Though most providers surveyed felt they did not have a lot of knowledge of NIPT at the time, the majority felt it could be offered to test for trisomy 21 and other aneuploidies.
Possible psychological benefits arising from the introduction of NIPT into clinical practice were predicted to include: less negative psychological impact for parents who terminate a pregnancy earlier based on NIPT results obtained early in the pregnancy; more time for parents to contemplate a decision to terminate while it is still an option; or more time to prepare mentally and physically for the birth of a child with a genetic condition (Hall, Bostanci, & Wright, 2010) . Providers have also expressed concern that with the ease and simplicity of NIPT for aneuploidy, NIPT may lead to non-invasive testing for late-onset and non-medical traits of the fetus (Benn & Chapman, 2009 ). Furthermore, the Down syndrome community has expressed fears that this earlier test in pregnancy could lead to an increase in the number of patients choosing to terminate pregnancies found to have Down syndrome (King, 2012; Rochman, 2012) .
As prenatal clinics implement NIPT for aneuploidy, an important factor to consider is the informed consent process. In terms of test structure, NIPT is a blood draw similar to maternal serum screening. However, the results of these two tests provide very different degrees of insight into the genetic makeup of the pregnancy and concern exists regarding patient perception of potential test results (Newson, 2008) . A study conducted in France investigated women who were counseled about maternal serum screening and whether they understood the information they were given in order to make a truly informed decision. They found that patients' perceptions on issues surrounding the test, including risks to have a child with Down syndrome and the meaning of a false positive result, were not well understood. The study quotes that 12% of patients felt completely uninformed and 47% felt partially uninformed of the specifics of the test (Favre et al., 2007) . Though NIPT is different from maternal serum screening, this study shows that patients already feel they are uninformed in one type of prenatal screening. The additional discussion needed to explain NIPT raises the possibility that patients will experience information overload which can undermine informed consent (Schmitz, 2012) . The purpose of informed consent is to provide all relevant information in order to allow the patient to maintain autonomy and make decisions in the absence of deceit and coercion. As NIPT becomes part of routine medical care for high-risk patients, it is possible that women will feel obligated to undergo testing, which challenges informed decision-making (Deans & Newson, 2011) . Healthcare providers should not assume that all women would opt for this testing simply because it is available. A thoughtful discussion about NIPT should highlight the benefit of the test being non-invasive when compared to CVS or amniocentesis as well as the idea that since it is nearly diagnostic for the conditions tested, it has the potential to provide powerful information and not all patients may wish to receive this information prenatally. This is especially important as more healthcare providers begin offering NIPT to all patients, rather than only to those considered high risk.
The purpose of the present study was to identify how genetic counselors have incorporated NIPT into their clinical setting and how NIPT has changed the landscape of prenatal genetic counseling in their practice with special attention paid to the informed consent process.
METHODS

STUDY DESIGN
We invited genetic counselors to complete an online anonymous survey pertaining to the integration of NIPT into their clinical practice. They were asked to provide statistics on the number of patients, types of patients, and circumstances in which they offer NIPT. We queried participants regarding their experience with NIPT results, both positive and negative. Furthermore, we asked participants to share information on their current practices for informed consent regarding NIPT as well as their thoughts for the future of NIPT in clinical practice.
SAMPLE AND RECRUITMENT
Brandeis University Committee for Protection of Human Subjects approved this study. An e-blast was sent to all NSGC members on the NSGC listserv. A reminder eblast was emailed approximately three weeks after the initial invitation to participate. We directed the recruitment notice (Appendix A) towards prenatal genetic counselors practicing in a prenatal clinic setting. Only those that indicated they were currently practicing as a prenatal genetic counselor were eligible to complete the survey.
DATA COLLECTION AND DATA ANALYSIS
We developed and distributed the research tool as an online anonymous survey using Qualtrics®. It was available from October 10, 2012 until November 14, 2012. The survey contained multiple choice questions in the form of single and multiple selections,
as well as open-ended responses (Appendix B). The survey consisted of a demographics section followed by a question asking whether respondents had incorporated NIPT into their clinical practice. Only those who had integrated NIPT into their practice at the time of the survey were eligible to complete the entire survey. We asked participants who indicated they had not integrated NIPT a series of questions pertaining to potential future integration of NIPT and then they exited the survey. The majority of the information obtained came from participants who indicated they had already incorporated NIPT into their clinical practice.
We completed data analysis using SPSS 19.0.0 for calculating descriptive statistics and correlations among the data.
RESULTS
DEMOGRAPHICS
There were 206 survey respondents spanning all six NSGC regions ( (Figure 1 ). Participants specified they usually refer to the technology of utilizing cell free DNA to detect aneuploidies non-invasively as NIPT (53.7%). Another 37.7% of participants routinely refer to this testing as cell-free fetal DNA testing, 4.6% refer to it by the brand name of the test, 2.9% refer to it as non-invasive prenatal diagnosis (NIPD), and 1.1% use more than one of the above-mentioned terms to describe the test to patients. Most participants (61.5%) revealed that the NIPT discussion has made genetic counseling sessions longer, whereas 28.4% said that it varies, and 10.1% indicated session length has not changed. Respondents were able to select more than one lab they use for NIPT and the ma- We asked respondents to assume a patient was AMA and then indicate if they would discuss NIPT in a number of different scenarios (Table 2) . We then asked respondents to assume a patient was non-AMA and then indicate if they would discuss NIPT in the same clinical scenarios. Regardless of clinical scenario, fewer counselors indicated they would discuss NIPT with non-AMA patients compared to AMA patients.
Counselors were significantly less likely to discuss NIPT with non-AMA patients than with AMA patients in the following scenarios: referred for first trimester screening; referred for diagnostic testing; maternal serum screening result is negative; a negative first trimester screen with at least one ultrasound marker, but together do not increase the risk for aneuploidy above the lab cut-off; any structural fetal anomaly on ultrasound; nuchal translucency >3.0mm; and family history of trisomy. When asked about the frequency with which they had seen patients with a positive NIPT result, 24 respondents (19.2%) had never had a patient with a positive NIPT result, 68 respondents (54.4%) had 1-5 patients with positive NIPT results, 26 respondents (20.8%) had 6-10 patients, and 7 respondents (5.6%) had 11 or more patients with a positive NIPT result. To gain more insight into pregnancy outcomes following positive NIPT results, we asked respondents to indicate what their experiences had been (Table 3) . We found that 70.3% of respondents had had one or more patients in their clinic elect to continue their pregnancy without confirming the positive NIPT result with invasive testing.
An additional 14.6% of respondents indicated they had had at least one patient terminate a pregnancy in their clinic based on NIPT results only. Further, 36.1% of respondents indicated they worked in a clinic that had had one or more patients whose invasive testing did not confirm the positive NIPT result they had previously received. as relief when a normal result was uncovered through invasive techniques. Six respondents (3.8%) indicated they had a false negative NIPT result discovered upon invasive diagnostic testing and one respondent (0.6%) revealed they had a patient who had a negative NIPT result that was later found to be incorrect upon the birth of the child. In this instance, the baby had Down syndrome at birth following a positive maternal serum screen and a negative NIPT result.
INFORMED CONSENT PROCESS
We asked participants to share their current clinical practices for consenting patients for NIPT as well as their thoughts for the future. Participants could choose all responses that applied, and all respondents (100%) indicated that genetic counselors consent for NIPT in their clinic. Maternal fetal medicine specialists (31.8%) are also consenting patients for NIPT. We asked respondents to select which health care provider(s) is/are appropriate to consent for NIPT. Again, participants could choose all that applied and 97.7% selected genetic counselors, 60.3% selected maternal fetal medicine specialists, 9.8% chose obstetricians, 8.0% chose nurse practitioners, and 5.2% selected midwives.
Most respondents (62.2%) indicated they obtain consent for NIPT verbally Slighty less than half of respondents (45.1%) indicated that there should be a separate informed consent form specific to NIPT, whereas 22.0% did not think there should be a separate consent form, and 32.9% were undecided. In addition, when respondents were asked how well they felt their patients understood the difference in detection rates between NIPT and maternal serum screening for chromosomal aneuploidies, most respondents (61.3%) felt that their patients fully understand the difference, 9.2% of respondents believed that patients do not really understand the difference, and 29.4% said it was hard to assess. In order to judge patient understanding, respondents indicated they do one or more of the following: take note of questions the patient asks (93.9%); ask the patient directly if they understand (76.7%); observe facial expressions (70.6%); and observe patient body language (60.7%). There was no significant difference between how well genetic counselors felt their patients understood NIPT and how they obtained informed consent.
We asked respondents to list the four most important points they believe should be included in a discussion about NIPT with patients. The following themes emerged from their responses: if they get a positive NIPT result then follow up with a CVS or amniocentesis is recommended; NIPT is a screening test and is not diagnostic; NIPT only detects certain chromosome aneuploidies; cost and insurance coverage should be mentioned; NIPT has a superior detection rate compared to other types of prenatal screening tests; and there is a possibility for false positives and false negatives (Table 4) . Genetic counselors are trained specifically in these areas and will continue to play a vital role in patient education and obtaining informed consent, especially when NIPT becomes more widely available.
At this time, NIPT can only be used clinically to detect certain aneuploidies and for sex determination. However, whole genome sequencing by NIPT of the fetus has recently been demonstrated in the research setting (Fan et al., 2012) . Opinions of genetic counselors from this study regarding the future integration of NIPT revealed concern over the fact that technology is advancing much more rapidly than knowledge of genes, their variants, and the implications of those variants for patients. Respondents acknowledged the increasing need for genetic counselors in settings where healthcare providers offer patients these types of tests.
After we completed data collection for this study, ACOG and the Society for Maternal-Fetal Medicine released a committee opinion statement pertaining to the incorporation of NIPT into clinical practice. The recommendation from this group as of December 2012 is to offer NIPT as a first screening option to patients that are considered high risk for having a fetus with an aneuploidy, and also to offer NIPT as a second screening option if a patient receives a positive maternal serum screening result. Upon receipt of a positive NIPT result, ACOG recommends confirmation of results with CVS or amniocentesis since false positive results are possible with this testing (ACOG, 2012) . ACMG also released guidelines, which recommend pre-test counseling for NIPT as well as post-test counseling for screen positive individuals (Gregg, et al., 2013) . Furthermore, NSGC recommends that only patients at increased risk for a chromosome aneuploidy should be offered NIPT and diagnostic testing is recommended to confirm positive results (Wilson, et al., 2013) . In this study, we queried genetic counselors as to whom they offer testing prior to any of these statement releases. Consistent with these recommendations, we found that most genetic counselors offered NIPT to women of AMA and did not offer it to women who were not AMA and who present to clinic for first trimester screening. This is not surprising, considering that this is how the test is marketed to medical professionals (SequenomInc., 2012) . Of note is we found that 14.6% of respondents indicated that they had had at least one patient who terminated a pregnancy based only on NIPT results. We did not ask if there were any ultrasound findings in these cases, and so we cannot assume that the NIPT result was the only factor in decision-making.
STUDY LIMITATIONS
The number of study participants was 206 total respondents, 181 of which indicated they had incorporated NIPT and therefore were responsible for the bulk of the data analyzed. There may have been a sample bias because the subject of the e-blast included the term "NIPT", and genetic counselors may have been more likely to complete the survey if their clinic had already incorporated NIPT. Furthermore, we recruited through NGSC and therefore only NSGC members received the e-blast recruitment email, though it was possible for colleagues to forward the recruitment email to non-members.
We did find some discrepancy in number of respondents for two questions that essentially asked the same thing. Respondents were not required to answer every question in the survey, which caused this inconsistency. In particular, we asked respondents about positive NIPT results on two occasions, however in the second question pertaining to positive NIPT results, participants could only fill in a number if they selected a certain answer for the question immediately before (Appendix B).
CONCLUSION
We surveyed prenatal genetic counselors to determine how they have incorporated NIPT into prenatal genetic counseling since the launch of the first test in 2011. We found that those who had incorporated NIPT into their clinic have mostly offered it to women at increased risk for aneuploidy, which is consistent with the newly released recommendations of ACOG, ACMG, and NSGC with regard to NIPT prenatal genetic screening. Respondents mostly gathered informed consent for NIPT verbally and indicated genetic counselors obtain informed consent from patients. Nearly half of respondents believe there should be a separate informed consent for NIPT and the discussion surrounding this test should highlight its screening nature, its superior detection rate compared to other screening methods, the limited number of conditions it can screen for, and the recommendations for diagnostic testing following a positive result. Future studies should address patient understanding of NIPT following genetic counseling to determine the best method for obtaining true informed consent as well as verify that informed consent for NIPT is being obtained as a wider array of healthcare providers begin to order this test.
APPENDIX A. Recruitment Notice
Subject: Student Research Project -NIPT: Current Utilization and Implications for the Future of Prenatal Genetic Counseling
Are you Currently Practicing as a Prenatal Genetic Counselor in a Prenatal Clinic?
If you are, I invite you to participate in a research study investigating the current integration and future directions of non-invasive prenatal testing (NIPT).
The purpose of this research study is to learn how genetic counselors in all parts of the United States and Canada are currently incorporating NIPT into clinical practice in the hopes of defining a direction for the future integration of NIPT.
Participation in this study is available to all prenatal genetic counselors who are currently working in a prenatal clinic setting. This study consists of an anonymous online survey that will take approximately 20-30 minutes to complete. Participation is anonymous and voluntary. You may discontinue participation at any time.
Participants will have the option to enter a draw to win one of two $50 gift cards to Amazon.com upon completion of the survey.
If you are interested in answering questions pertaining to your current experience with NIPT with the aim of establishing a standard of care for the future, please follow the link to the survey below.
Link to survey
If you have any comments or questions, please feel free to contact me by email at abuchana@brandeis.edu, or the Brandeis University faculty sponsor, Judith Tsipis, at tsipis@brandeis.edu. Thank you in advance for your participation. Non-invasive prenatal testing (NIPT) involves measuring cell free fetal DNA in maternal blood to detect fetal aneuploidies. This test became clinically available in November 2011 for measuring trisomy 21. Since this time, other tests have emerged that also detect trisomies 13 and 18, and monosomy X. Currently there are no clear guidelines for how NIPT should be integrated into clinical practice. The purpose of this research study is to determine the current integration of NIPT and the future direction of NIPT in the hopes of establishing a standard of care for genetic counseling. Your insight on this topic will help to delineate current practices as well as directions for the future of NIPT in clinical practice.
For the purpose of consistency throughout the survey, "NIPT" will be used to describe the technology of measuring cell free fetal DNA in maternal blood to predict fetal aneuploidies.
Upon completion of the survey, you will have the option to enter a draw to receive one of two $50 gift cards for Amazon.com.
By clicking the forward button below you are consenting to participate in this study.
Q1 Are you currently practicing as a prenatal genetic counselor?  Referred for first trimester screening (1)  Referred for diagnostic testing (2)  Maternal serum screen result is negative (3)  Maternal serum screen result is positive (4)  Negative first trimester screen plus one or more soft markers on ultrasound (I.e., echogenic focus, choroid plexus cysts, echogenic bowel, thickened nuchal fold, hy-dronephrosis) that when combined with first trimester screen results does not increase the risk for aneuploidy to above the lab cut-off (5)  Negative first trimester screen plus one or more soft markers on ultrasound (I.e., echogenic focus, choroid plexus cysts, echogenic bowel, thickened nuchal fold, hydronephrosis) that when combined with first trimester screen results does increase the risk for aneuploidy to above 1:270 (6)  Multiple soft markers found on ultrasound regardless of maternal serum screen result (7)  Nuchal translucency is >3.0mm (8)  Nuchal translucency is >3.5mm (9)  Cystic hygroma found on ultrasound (10)  Presence of any structural fetal anomaly on ultrasound (11)  History of a previous pregnancy with a trisomy (T13, T18, T21) (12)  Family history of trisomy (T13, T18, T21) other than a previous pregnancy (13)  Other, please specify: (14) ____________________ Q19 For pregnant women that are not AMA, in which of the following scenarios do you discuss NIPT with the patient? (Check all that apply):
 Referred for first trimester screening (1)  Referred for diagnostic testing (2)  Maternal serum screen result is negative (3)  Maternal serum screen result is positive (4)  Negative first trimester screen plus one or more soft markers on ultrasound (I.e., echogenic focus, choroid plexus cysts, echogenic bowel, thickened nuchal fold, hydronephrosis) that when combined with first trimester screen results does not increase the risk for aneuploidy to above the lab cut-off (5)  Negative first trimester screen plus one or more soft markers on ultrasound (I.e., echogenic focus, choroid plexus cysts, echogenic bowel, thickened nuchal fold, hydronephrosis) that when combined with first trimester screen results does increase the risk for aneuploidy to above 1:270 (6)  Multiple soft markers found on ultrasound regardless of maternal serum screen result (7)  Nuchal translucency is >3.0mm (8)  Nuchal translucency is >3.5mm (9)  Cystic hygroma found on ultrasound (10)  Presence of any structural fetal anomaly on ultrasound (11)  History of a previous pregnancy with a trisomy (T13, T18, T21) (12)  Family history of trisomy (T13, T18, T21) other than a previous pregnancy (13) Answer If In your clinic, have you received a positive test result from NIPT that was later found to be negative by invasive diagnostic testing? yes Is Selected Q41 Please describe the clinical and psychosocial issues that accompanied the situation(s).
Q42
In your clinic, have you received a negative result from NIPT that was found to be incorrect by follow-up invasive diagnostic testing?
Answer If In your clinic, have you received a negative result from NIPT that was later found to be incorrect by follow-up invasive diagnostic testing? yes Is Selected Q43 Please describe the clinical and psychosocial issues that accompanied the situation(s).
Q44
In your clinic, have you received a negative result from NIPT that was found to be incorrect upon birth of the child?
Answer If In your clinic, have you received a negative result from NIPT that was found to be incorrect upon birth of the child? yes Is Selected Q45 Please describe the clinical and psychosocial issues that accompanied the situation(s).
